Magnera reported a 2% increase in revenue to $700 million for the December quarter, with adjusted EBITDA up 8% to $84 million and an improved margin of 12%.
The company projects fiscal 2025 adjusted free cash flow in the range of $70 million to $95 million, with a focus on deleveraging to achieve a targeted leverage ratio of 3x.
Synergy realization from the merger is progressing well, with $55 million in synergies expected, contributing to the company's long-term growth and margin improvement.
Magnera anticipates low to mid-single-digit growth in developed markets and faster growth in emerging markets, driven by trends such as a growing middle class, increased life expectancy, and heightened focus on personal and environmental health.
The company is actively managing working capital, optimizing cash flow, and focusing on higher-value product categories while navigating global supply-demand dynamics and inflationary pressures.